Talquetamab
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 155 publications
Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.
Journal: Oncology (Williston Park, N.Y.)
Published: June 22, 2026
Practical Management of Bispecific Antibodies in Multiple Myeloma.
Journal: JCO oncology practice
Published: June 17, 2026
A plain language summary describing how talquetamab affects the way people with multiple myeloma feel and function in the MonumenTAL-1 study.
Journal: Future oncology (London, England)
Published: June 16, 2026
Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.
Journal: The New England journal of medicine
Published: June 15, 2026
Condensed vs. Standard Step-Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma.
Journal: European journal of haematology
Published: April 02, 2026
The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review.
Journal: American journal of hematology
Published: March 19, 2026
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis.
Journal: American journal of hematology
Published: March 04, 2026
Supportive care for talquetamab-related dysgeusia in multiple myeloma: mixed-methods evidence, nutrition-focused flowchart, and digital companion concept.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: February 20, 2026
A rare case of fulminant talquetamab-induced myocarditis presenting as a STEMI mimicker.
Journal: Cardio-oncology (London, England)
Published: February 12, 2026
Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma.
Journal: American journal of hematology
Published: February 07, 2026
Last Updated: 06/30/2026